HE4 - A novel promising serum marker in the diagnosis of ovarian carcinoma

European Journal of Gynaecological Oncology

Volumn 32, Issue 6, 2011, Pages 605-610

  Langmar Z ^a   Nemeth M ^b   Vlesko G ^a   Kiraly M ^c   Hornyak L ^d   Bosze P ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Saint Stephen Hospital   (Hungary)

^c Endocrinology and Diabetology   (Hungary)

^d Dept of Dentistry and Oral Surgery   (Hungary)

Author keywords

HE4; Ovarian cancer; Risk of ovarian malignancy algorithm; Serum marker

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RECURRENCE; OVARY CARCINOMA; POSTMENOPAUSE; PREMENOPAUSE; REVIEW;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEINS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84855491105     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Moore R.G., Bast R.C. Jr: "Biomarkers for ovarian cancer". In: Bast R.C. Jr, Markman M. (eds.): Ovarian Cancer. London, UK, Remedica, 2009, 35.
2. Li J., Dowdy S., Tipton T., Podratz K., Lu W.G., Xie X., Jiang S.W.: "HE4 as a biomarker for ovarian and endometrial cancer management". Expert Rev. Mol. Diagn. 2009, 9, 555.
3. Moore R.G., MacLaughlan S., Bast R.C. Jr.: "Current state of biomarker development for clinical application in epithelial ovarian cancer". Gynecol. Oncol., 2010, 116, 240.
4. Plebani P.M., Melichar P.M.: "ROMA or death: advances in epithelial ovarian cancer diagnosis". Clin. Chem. Lab. Med., 2011, 49, 443.
5. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A. et al.: "Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients". J. Natl. Cancer Inst., 2006, 98, 172.
6. Paulsen T., Kjaerheim K., Kaem J., Tretli S., Tropé C.: "Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals". Int. J. Gynecol. Cancer, 2006, 16 (suppl. 1), 11.
7. Engelen M.J., Kos H.E., Willemse P.H., Aalders J.G., de Vries E.G., Schaapveld M. et al.: "Surgery by consultant gynaecologic oncologists improves survival in patients with ovarian carcinoma". Cancer, 2006, 106, 589.
8. Giede K.C., Kieser K., Dodge J., Rosen B.: "Who should operate on patients with ovarian cancer? An evidence-based review". Gynecol. Oncol., 2005, 99, 447.
9. Kirchhoff C., Habben I., Ivell R., Krull N.: "A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors". Biol. Reprod., 1991, 45, 350.
10. Kirchhoff C., Osterhoff C., Habben I., Ivell R.: "Cloning and analysis of mRNA expressed specifically in the human epididymis". Int. J. Androl., 1990, 13, 155.
11. Hellström I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M. et al.: "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma". Cancer Res., 2003, 63, 3695.
12. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T. et al.: "The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass". Gynecol. Oncol., 2008, 108, 402.
13. Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M.C., Allard W.J. et al. "A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass". Gynecol. Oncol., 2009, 112, 40.
14. Huhtinen K., Suvitie P., Hiissa J., Junnila J., Huvila J., Kujari H. et al.: "Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts". Br. J. Cancer, 2009, 100, 1315.
15. Nolen B., Velikokhatnaya L., Marrangoni A., De Geest K., Lomakin A., Bast R.C. Jr., Lokshin A.: "Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass". Gynecol. Oncol., 2010, 117, 440.
16. Abdel-Azeez H.A., Labib H.A., Sharaf S.M., Refai A.N.: "HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses". Asian. Pac. J. Cancer Prev., 2010, 11, 111.
17. Wang S., Dong L., Li H., Wang M.: "The application of HE4 in diagnosis of gynecological pelvic malignant tumor". Clin. Oncol. Cancer Res., 2009, 6, 72.
18. Shah C.A., Lowe K.A., Paley P., Wallace E., Anderson G.L., Mcintosh M.W. et al.: "Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125". Cancer Epidemiol. Biomarkers Prev., 2009, 18, 1365.
19. Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G.: "HE4: a new potential early biomarker for the recurrence of ovarian cancer". Tumour Biol., 2010, 31, 113.
20. Holcomb K., Miller C., Vucetic Z., Knapp R.: "Human epididymis protein 4 increases specificity for the detection of invasive epithelial ovarian cancer in premenopausal women presenting with an adnexal mass". Gynecol. Oncol., 2011, 120 (suppl. 1), S69.
21. Hellström I., Heagerty P.J., Swisher E.M., Liu P., Jaffar J., Agnew K., Hellstrom K.E.: "Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms". Cancer Lett., 2010, 296, 43.
22. Andersen M.R., Goff B.A., Lowe K.A., Scholler N., Bergan L., Drescher C.W. et al.: "Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer". Gynecol. Oncol., 2010, 116, 378.
23. Kang S., Kong S., Park S., Seo S., Kim J.: "Serum HE4 level is an independent risk factor of surgical outcome and prognosis of epithelial ovarian cancer". Gynecol. Oncol., 2011, 120 (suppl. 1), S77.
24. Dahl Steffensen K., Waldström M., Brandslund I., Jakobsen A.: "Prognostic impact of prechemotherapy HE4 and CA-125 levels in patients with ovarian cancer". Gynecol. Oncol., 2011, 120 (suppl. 1), S77.
25. Moore R.G., Jabre-Raughley M., Brown A.K., Robison K.M., Miller M.C., Allard W.J. et al.: "Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass". Am. J. Obstet. Gynecol., 2010, 203, 228.e1.
26. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinkas J.G.: "A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer". Br. J. Obstet. Gnyaecol., 1990, 97, 922.
27. Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M. et al.: "The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?" Clin. Chem. Lab. Med., 2011, 49, 521.
28. Kim Y.M., Whang D.H, Park J., Kim S.H., Lee S.W., Park HA. et al.: "Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population". Clin. Chem. Lab. Med., 2011, 49, 527.
29. Van Gorp T., Cadron I., Despierre E., Daemen A., Leunen K., Amant F. et al.: "HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm". Br. J. Cancer, 2011, 104, 863.
30. Jacob F., Meier M., Caduff R., Goldstein D., Pochechueva T., Hacker N. et al.: "No benefit from combining HE4 and CA125 as ovarian tumour markers in a clinical setting". Gynecol. Oncol., 2011, 121, 487.
31. Moore R.G., MacLaughlan S.: "A novel approach for the risk assessment of a pelvic mass for ovarian cancer". Female Patient, 2009, 34, 31.